```
SESSION RESUMED IN FILE 'REGISTRY' AT 12:10:11 ON 11 SEP 2009
FILE 'REGISTRY' ENTERED AT 12:10:11 ON 11 SEP 2009
COPYRIGHT (C) 2009 American Chemical Society (ACS)

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY     SESSION
FULL ESTIMATED COST                                        1.92        2.14

=> d his

     (FILE 'HOME' ENTERED AT 12:04:42 ON 11 SEP 2009)

     FILE 'REGISTRY' ENTERED AT 12:04:53 ON 11 SEP 2009
L1             STRUCTURE UPLOADED
L2          11 S L1 SSS SAM
L3             STRUCTURE UPLOADED
L4          11 S L3 SSS SAM

=>
Uploading C:\Program Files\STNEXP\Queries\10_614362 NK1 Antagonist compound 7
Structure_c.str

L5      STRUCTURE UPLOADED

=> d L5
L5 HAS NO ANSWERS
L5                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s L5 SSS SAM
SAMPLE SEARCH INITIATED 12:10:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       21 TO ITERATE
```

100.0% PROCESSED 21 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 146 TO 694
PROJECTED ANSWERS: 2 TO 124

L6 2 SEA SSS SAM L5

=> d scan L6

L6 2 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4-Quinolinecarboxamide, 8-fluoro-3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-
MF C25 H21 F N2 O2

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 2 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4-Quinolinecarboxamide, 7-fluoro-3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-
MF C25 H21 F N2 O2

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d his

     (FILE 'HOME' ENTERED AT 12:04:42 ON 11 SEP 2009)

     FILE 'REGISTRY' ENTERED AT 12:04:53 ON 11 SEP 2009
L1   STRUCTURE UPLOADED
L2   11 S L1 SSS SAM
L3   STRUCTURE UPLOADED
L4   11 S L3 SSS SAM
L5   STRUCTURE UPLOADED
L6   2 S L5 SSS SAM

=> s L4 SSS FULL
FULL SEARCH INITIATED 12:11:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   357 TO ITERATE

100.0% PROCESSED   357 ITERATIONS   169 ANSWERS
SEARCH TIME: 00.00.01

L7   169 SEA SSS FUL L3

=> file hcaplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   188.28   188.50

FILE 'HCAPLUS' ENTERED AT 12:11:36 ON 11 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Sep 2009 VOL 151 ISS 12
FILE LAST UPDATED: 10 Sep 2009 (20090910/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

```
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information.  This enhancement may impact record import into
database management software.  For additional information, refer
to NEWS 9.

=> d his

     (FILE 'HOME' ENTERED AT 12:04:42 ON 11 SEP 2009)

     FILE 'REGISTRY' ENTERED AT 12:04:53 ON 11 SEP 2009
L1             STRUCTURE UPLOADED
L2          11 S L1 SSS SAM
L3             STRUCTURE UPLOADED
L4          11 S L3 SSS SAM
L5             STRUCTURE UPLOADED
L6           2 S L5 SSS SAM
L7         169 S L4 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 12:11:36 ON 11 SEP 2009

=> s L7
L8          92 L7

=> s L8 and (COPD or (chronic(W)obstructive(W)pulmonary(W)disease) or emphysema or
asthma)
          4998 COPD
        268397 CHRONIC
         17845 OBSTRUCTIVE
        112589 PULMONARY
       1182405 DISEASE
          9994 CHRONIC(W)OBSTRUCTIVE(W)PULMONARY(W)DISEASE
          5032 EMPHYSEMA
         45510 ASTHMA
L9          16 L8 AND (COPD OR (CHRONIC(W)OBSTRUCTIVE(W)PULMONARY(W)DISEASE)
             OR EMPHYSEMA OR ASTHMA)

=> s L9 NOT pd>20040610
       6852770 PD>20040610
                 (PD>20040610)
L10          0 L9 NOT PD>20040610

=> s L9 and (inhalable or respirable)
          1368 INHALABLE
          4447 RESPIRABLE
L11          1 L9 AND (INHALABLE OR RESPIRABLE)

=> d L11 TI AB IBIB

L11  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Pharmaceutical compositions for the treatment of respiratory and
     gastrointestinal disorders
AB   The present invention relates to novel pharmaceutical compns. comprising
     at least 1 EGFR kinase inhibitor and at least one addnl. active compd.
     selected from .beta.-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP
     kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes
     for prepg. the compns. and the use thereof as drugs in the treatment of
     respiratory or gastrointestinal complaints, as well as inflammatory
     diseases of the joints, the skin or the eyes.  Thus, an inhalable
```

powder contained an EGFR kinase inhibitor 150, formoterol fumarate dihydrate 50, and lactose 12,300 mg/capsule.

ACCESSION NUMBER: 2006:149262 HCAPLUS
DOCUMENT NUMBER: 144:239931
TITLE: Pharmaceutical compositions for the treatment of respiratory and gastrointestinal disorders
INVENTOR(S): Jung, Birgit; Himmelsbach, Frank
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG
SOURCE: PCT Int. Appl., 321 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015775	A2	20060216	WO 2005-EP8385	20050803
WO 2006015775	A3	20070518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20060035893	A1	20060216	US 2005-189643	20050726
CA 2575541	A1	20060216	CA 2005-2575541	20050803
EP 1784224	A2	20070516	EP 2005-773706	20050803
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008509177	T	20080327	JP 2007-525227	20050803
US 20090017036	A1	20090115	US 2008-202784	20080902

PRIORITY APPLN. INFO.:
EP 2004-18808 A 20040807
US 2005-189643 A1 20050726
WO 2005-EP8385 W 20050803

OTHER SOURCE(S): MARPAT 144:239931

=> d his

(FILE 'HOME' ENTERED AT 12:04:42 ON 11 SEP 2009)

FILE 'REGISTRY' ENTERED AT 12:04:53 ON 11 SEP 2009
L1 STRUCTURE UPLOADED
L2 11 S L1 SSS SAM
L3 STRUCTURE UPLOADED
L4 11 S L3 SSS SAM
L5 STRUCTURE UPLOADED
L6 2 S L5 SSS SAM
L7 169 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 12:11:36 ON 11 SEP 2009
L8 92 S L7

```
L9            16 S L8 AND (COPD OR (CHRONIC(W)OBSTRUCTIVE(W)PULMONARY(W)DISEASE)
L10            0 S L9 NOT PD>20040610
L11            1 S L9 AND (INHALABLE OR RESPIRABLE)

=> s L9 and (anticholinergic or muscarinic)
          5611 ANTICHOLINERGIC
         28091 MUSCARINIC
L12           9 L9 AND (ANTICHOLINERGIC OR MUSCARINIC)

=> s L12 NOT L11
L13           9 L12 NOT L11

=> focus L13
PROCESSING COMPLETED FOR L13
L14            9 FOCUS L13 1-

=> d L14 1-5 TI AB

L14  ANSWER 1 OF 9  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as
     inhibitors of phosphodiesterase IV isozymes
AB   Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2;
     m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y =
     =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl,
     fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB =
     independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl;
     or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one
     of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2,
     (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl,
     Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F. Cl, alkynyl, R16,
     OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted
     carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and
     R6 taken together with the atoms to which they are attached =
     (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd.
     monocyclic or fused polycyclic ring; D = (un)substituted carboxy,
     carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or
     (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd.
     as inhibitors of PDE4 (no data).  For example,
     2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with
     (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of
     1-hydroxybenzotriazole.bul.H2O and
     1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to
     give the pyridinecarboxamide II (R = Me) in 38% yield.  Sapon. using aq.
     LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield.
     I are useful in the treatment of diseases regulated by the activation and
     degranulation of eosinophils, esp. asthma, chronic bronchitis,
     and chronic obstructive pulmonary
     disease (no data).  In addn., I may be used in combination therapy
     with a wide variety of other therapeutic agents.

L14  ANSWER 2 OF 9  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Genetic markers in tachykinin NK1 receptor gene TACR1 that correlate with
     asthma disorders
AB   Polymorphisms in the exon 2 LD block of gene TACR1 encoding tachykinin
     receptor 1 are shown by assocn. anal. to be a susceptibility gene for
     asthma.  Methods of diagnosis of susceptibility to asthma
     , of decreased susceptibility to asthma and protection against
     asthma, are described, as are methods of treatment for
     asthma.

L14  ANSWER 3 OF 9  HCAPLUS  COPYRIGHT 2009 ACS on STN
```

TI Synthesis of 3H-pyrrolo[2,3-d]pyrimidine derivatives and use as phosphodiesterase VII inhibitors and in combination with other agents
AB The invention concerns the synthesis of 3H-pyrrolo[2,3-d]pyrimidine derivs., their physiol. acceptable salts, stereoisomers, solvates, mixts. thereof and their use as phosphodiesterase VII inhibitors in the treatment of diseases that are influenced by the phosphodiesterase VII regulation of human eosinophil activation and degranulation. Osteoporesis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, AIDS, autoimmune and heart diseases can be treated with the drugs. Thus the synthesis of 5-isopropyl-4-oxo-7-p-tolyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid Et ester and analog compds. is described along with injection, suppository, tablet and other formulations.

L14 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of indole compounds having CRTH2 antagonist activity for treating allergic diseases, asthma, and inflammatory conditions
AB Compds. of general formula I (wherein R is Ph optionally substituted with one or more halo substituents) and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are antagonists at the CRTH2 receptor and are useful in the treatment of conditions mediated by PGD2 or other agonists binding to CRTH2. These include allergic diseases, asthmatic conditions and inflammatory diseases. A process for prepg. I was addnl. claimed. Example compd. II was prepd. by reacting 2-(phenylsulfonyl)benzaldehyde with 2-(5-fluoro-2-methyl-1H-indol-1-yl)acetic acid and sapon. of the resulting ester. In an assay measuring inhibition of 13,14-dihydro-15-keto-prostaglandin D2 induced blood eosinophilia in rats, II had an ED50 of 0.0025 .mu.g/mL.

L14 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceutical compositions comprising novel anticholinergic agents and NK1-receptor antagonists for the treatment of respiratory tract diseases
AB The invention relates to novel pharmaceutical compns. comprising novel anticholinergic agents and NK1-receptor antagonists, method for prodn. and use thereof in the treatment of respiratory diseases. Thus an inhalation capsule contained (microgram/capsule): 2,2-Diphenylpropionic acid scopine ester methobromide 200; N-[2-(3,5-Bis-trifluoromethylphenyl)-ethyl]-2-{4-[(3-hydroxypropyl)methylamino]piperidin-1-yl}-N-methyl-2-phenylacetamide 150; lactose 12150.

=> d L14 6-9 TI AB

L14 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Type 4 phosphodiesterase inhibitors and therapeutic uses thereof
AB The invention discloses the use of type 4 phosphodiesterase inhibitors (PDE IV inhibitors) to treat diseases, as well as combinations of PDE IV inhibitors with other drugs.

L14 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of pyridazinyloximes as phosphodiesterase IV inhibitors.
AB Title compds. [I; R1, R2 = H, OH, OR8, SR8, SOR8, SO2R8, halo; R1R2 = OCH2O, OCH2CH2O; R3 = H, AR7, COAR7, CO2AR7, CONH2, NH2, etc.; R7 = H, CO2H, NH2, OH, etc.; R8 = (substituted) alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, etc.; A = null, (O, S, SO, SO2, imino-interrupted) alkylene, alkenylene, cycloalkylene; B = (substituted) aryl, heteroaryl; X = (O, S, SO, SO2, imino-interrupted) alkylene], were prepd. as phosphodiesterase IV inhibitors for treating osteoporosis, tumors,

cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS (no data). Thus, 3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazine was treated sequentially with chloroacetyl chloride, N-hydroxyphthalimide, ethanolamine, and 4-methoxybenzaldehyde to give 4-methoxybenzaldehyde O-[2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl]oxime.

L14 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of pyridazinylmethanoylphenylhydrazonomalonitriles as phosphodiesterase IV inhibitors.
AB Title compds. [I; R1, R2 = H, OH, OR5, SR5, SOR5, SO2R5, X; R1R2 = OCH2O, OCH2CH2O; R3, R31 = H, R5, OH, OR5, NH2, NHR5, NHCOR5, X, CO2H, CO2R5, CONH2, etc.; R4 = cyano, tetrazolyl; R5 = (fluoro-substituted) A, cycloalkyl, (CH2)nAr; A = (fluoro- and/or chloro-substituted) alkyl, alkenyl; Ar = Ph; n = 0-2; X = F, Cl, Br, iodo], were prepd. Thus, [3-(3,4-diethoxyphenyl)-5,6-dihydro-4H-pyridazine-1-yl]-(3-aminophenyl)methanone (prepn. given) was stirred with NaNO2 in aq. HCl for 1 h at -2.degree. to 0.degree.; malononitrile in H2O was added followed by stirring for 2 h to give a residue which was treated with KOH in MeOH to give 2-[[3-[1-[3-(3,4-diethoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]methanoyl]phenyl]hydrazono]malononitrile K salt. I were said to give a marked redn. of T cell proliferation. I are claimed for treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases, AIDS, etc.

L14 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes
AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aq. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

=> d L14 1,5 TI AB IBIB

L14 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes
AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl,

Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F. Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd. as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole.bul.H2O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

ACCESSION NUMBER: 2002:594842 HCAPLUS
DOCUMENT NUMBER: 137:154859
TITLE: Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes
INVENTOR(S): Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060896	A1	20020808	WO 2001-IB2726	20011224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2436544	A1	20020808	CA 2001-2436544	20011224
AU 2002222428	A1	20020812	AU 2002-222428	20011224
EE 200300361	A	20031215	EE 2003-361	20011224
HU 2003002891	A2	20031229	HU 2003-2891	20011224
EP 1373258	A1	20040102	EP 2001-273558	20011224
EP 1373258	B1	20050928		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016845	A	20040225	BR 2001-16845	20011224
JP 2004518689	T	20040624	JP 2002-561464	20011224
CN 1527830	A	20040908	CN 2001-823098	20011224
NZ 526531	A	20050225	NZ 2001-526531	20011224
AT 305467	T	20051015	AT 2001-273558	20011224
ES 2248231	T3	20060316	ES 2001-273558	20011224

US 20030027845	A1	20030206	US 2002-66503		20020131
US 6828333	B2	20041207			
IN 2003MN00626	A	20050211	IN 2003-MN626		20030620
ZA 2003004893	A	20040624	ZA 2003-4893		20030624
BG 107960	A	20041029	BG 2003-107960		20030701
NO 2003003399	A	20030925	NO 2003-3399		20030730
MX 2003006885	A	20031113	MX 2003-6885		20030730
US 20050049258	A1	20050303	US 2004-918820		20040813
US 7183293	B2	20070227			
US 20070161681	A1	20070712	US 2007-668915		20070130
PRIORITY APPLN. INFO.:			US 2001-265304P	P	20010131
			WO 2001-IB2726	W	20011224
			US 2002-66503	A3	20020131
			US 2004-918820	A3	20040813

OTHER SOURCE(S): MARPAT 137:154859
OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceutical compositions comprising novel anticholinergic agents and NK1-receptor antagonists for the treatment of respiratory tract diseases
AB The invention relates to novel pharmaceutical compns. comprising novel anticholinergic agents and NK1-receptor antagonists, method for prodn. and use thereof in the treatment of respiratory diseases. Thus an inhalation capsule contained (microgram/capsule): 2,2-Diphenylpropionic acid scopine ester methobromide 200; N-[2-(3,5-Bis-trifluoromethylphenyl)-ethyl]-2-{4-[(3-hydroxypropyl)methylamino]piperidin-1-yl}-N-methyl-2-phenylacetamide 150; lactose 12150.

ACCESSION NUMBER: 2004:41273 HCAPLUS
DOCUMENT NUMBER: 140:99643
TITLE: Pharmaceutical compositions comprising novel anticholinergic agents and NK1-receptor antagonists for the treatment of respiratory tract diseases
INVENTOR(S): Pairet, Michel; Meade, Christopher John Montague; Pieper, Michael P.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004724	A1	20040115	WO 2003-EP6667	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

```
          BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     DE 10230750          A1     20040122    DE 2002-10230750        20020709
     CA 2491451           A1     20040115    CA 2003-2491451         20030625
     AU 2003242754        A1     20040123    AU 2003-242754          20030625
     EP 1521580           A1     20050413    EP 2003-762508          20030625
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2005532378        T      20051027    JP 2004-518565          20030625
     US 20040048886       A1     20040311    US 2003-614362          20030707
PRIORITY APPLN. INFO.:                        DE 2002-10230750    A   20020709
                                              US 2002-407758P     P   20020903
                                              WO 2003-EP6667      W   20030625

OTHER SOURCE(S):         MARPAT 140:99643
REFERENCE COUNT:         7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d que
L3                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L7          169 SEA FILE=REGISTRY SSS FUL L3
L8           92 SEA FILE=HCAPLUS ABB=ON  L7
L9           16 SEA FILE=HCAPLUS ABB=ON  L8 AND (COPD OR (CHRONIC(W)OBSTRUCTIVE
                (W)PULMONARY(W)DISEASE) OR EMPHYSEMA OR ASTHMA)
L11           1 SEA FILE=HCAPLUS ABB=ON  L9 AND (INHALABLE OR RESPIRABLE)
L12           9 SEA FILE=HCAPLUS ABB=ON  L9 AND (ANTICHOLINERGIC OR MUSCARINIC)

L13           9 SEA FILE=HCAPLUS ABB=ON  L12 NOT L11
L14           9 FOC L13 1-


=> d que L9
L3                STR
```



Structure attributes must be viewed using STN Express query preparation.

L7 169 SEA FILE=REGISTRY SSS FUL L3

L8 92 SEA FILE=HCAPLUS ABB=ON L7

L9 16 SEA FILE=HCAPLUS ABB=ON L8 AND (COPD OR (CHRONIC(W)OBSTRUCTIVE (W)PULMONARY(W)DISEASE) OR EMPHYSEMA OR ASTHMA)